Revvity (NYSE:RVTY) Reaches New 1-Year High – What’s Next?

Shares of Revvity Inc. (NYSE:RVTY) reached a new 52-week high during mid-day trading on Tuesday . The company traded as high as $134.37 and last traded at $135.1170, with a volume of 117173 shares trading hands. The stock had previously closed at $128.49.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on RVTY. Sanford C. Bernstein started coverage on shares of Revvity in a report on Friday, June 26th. They set a “market perform” rating and a $115.00 target price for the company. Weiss Ratings upgraded Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 30th. Wolfe Research started coverage on Revvity in a research report on Tuesday, June 2nd. They set a “peer perform” rating for the company. UBS Group began coverage on Revvity in a report on Wednesday, September 9th. They issued a “neutral” rating and a $140.00 price objective for the company. Finally, Zacks Research raised Revvity from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 4th. Four equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $116.57.

Revvity Stock Up 6.1%

The company has a market capitalization of $15.21 billion, a P/E ratio of 65.12, a price-to-earnings-growth ratio of 2.26 and a beta of 1.09. The company has a 50-day moving average of $118.03 and a two-hundred day moving average of $103.47. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. The business had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm’s quarterly revenue was down 1.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts predict that Revvity Inc. will post 5.36 EPS for the current year.

Revvity Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Investors of record on Friday, October 23rd will be paid a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Friday, October 23rd. Revvity’s dividend payout ratio (DPR) is presently 13.33%.

Hedge Funds Weigh In On Revvity

Several large investors have recently made changes to their positions in the business. Ascentis Independent Advisors bought a new position in Revvity during the first quarter valued at approximately $29,000. Global Retirement Partners LLC bought a new stake in Revvity in the 2nd quarter worth approximately $51,000. SJS Investment Consulting Inc. grew its position in Revvity by 5,210.0% in the 1st quarter. SJS Investment Consulting Inc. now owns 531 shares of the company’s stock worth $47,000 after purchasing an additional 521 shares during the period. Summit Securities Group LLC raised its stake in Revvity by 294.6% during the 1st quarter. Summit Securities Group LLC now owns 663 shares of the company’s stock valued at $58,000 after buying an additional 495 shares during the last quarter. Finally, Contravisory Investment Management Inc. purchased a new stake in Revvity during the 1st quarter valued at $66,000. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.